Biocodex

Company snapshot

Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,700 employees, Biocodex generated net revenues of above €500 million in 2023, including 1/3 in France and 2/3 inte

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Biocodex. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Biocodex.

1. Jun 8, 2026 Clinical update

   STP226 — Phase 3

2. Jun 8, 2026 Clinical update

   Sb 241 — Approved

3. Jun 8, 2026 Clinical update

   STP237 — Phase 1

4. Jun 8, 2026 Clinical update

   STP218 — Phase 1

5. Jun 8, 2026 Clinical update

   BoWell - Sb252 — Phase 3

View all clinical trial activity →

• What is Biocodex?

  Biocodex is a pharma organization headquartered in GENTILLY, FR. Primary therapeutic focus areas include Dravet syndrome, Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3), Non-constipated Irritable Bowel Syndrome (IBS). NovaPharmaNews links 5 clinical program(s), 0 d

• Is Biocodex publicly traded?

  Biocodex appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Biocodex develop or market?

  We link 15 drug profile(s) where Biocodex is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/biocodex#company-drugs.

• What are the latest developments for Biocodex?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Biocodex focus on?

  Biocodex focuses on Dravet syndrome, Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3), Non-constipated Irritable Bowel Syndrome (IBS) based on our analysis of their pipeline programs and drug development activities.